Mucosal Barrier Restoration Protocol — UC in Remission

Carboxymethylcellulose (CMC) and polysorbate-80 reduce mucus pore size and alter the mucus microbiome in ways associated with barrier dysfunction and increased IBD prevalence. Removal of these additives is a foundational dietary step to prevent ongoing mucus layer erosion in UC remission.

Butyrate is the primary energy substrate for colonocytes and goblet cells, directly driving MUC2 production, upregulating trefoil factor expression, and tightening paracellular junctions. The literature reports that fermentable fibres (inulin, resistant starch, pectin) are the principal dietary route to sustained colonic butyrate generation.

Bile acids activate FXR and TGR5 receptors on intestinal epithelium, promoting barrier integrity, stem cell-driven regeneration, and tight junction maintenance. Diets that support a diverse secondary bile acid pool — high-fibre, low-saturated-fat — favour beneficial FXR/TGR5 signalling relevant to mucosal healing in UC remission.

Sleep fragmentation is associated with heightened systemic inflammation and impaired resolution biology, reducing the availability of SPMs required for active mucosal healing. While direct UC-specific sleep-barrier studies are limited in this article set, the resolution biology literature highlights that SPM biosynthesis is circadian-sensitive and disrupted by sleep dysregulation.

The vagus nerve's cholinergic anti-inflammatory pathway (CAP) inhibits pro-inflammatory cytokine release from intestinal macrophages and has been shown to reduce intestinal permeability and protect the epithelial glycocalyx. The literature reports that contemplative practices (mindfulness, slow-paced breathing, yoga) measurably enhance vagal tone and CAP activity.

Psychological stress activates intestinal mast cells, releasing histamine, tryptase, and prostaglandins that increase vascular permeability and drive protease-activated receptor signalling, contributing to barrier dysfunction. In UC remission, mapping and reducing stress-related and dietary mast cell triggers is reported in the literature as a practical adjunct to structural mucosal repair.

Exogenous butyrate supplementation has been reported to increase mucin production, expand goblet cell populations, upregulate TFF peptides, and reduce paracellular permeability via tight junction modulation. Both oral (sodium butyrate) and rectal (enema) formulations appear in the literature for colonic barrier support.

Resolvins, protectins, and maresins — collectively specialized pro-resolving mediators (SPMs) — are biosynthesised from omega-3 precursors (EPA and DHA) and actively drive resolution of mucosal inflammation, stimulate epithelial repair, and prevent chronification of barrier dysfunction in IBD. The literature identifies omega-3 supplementation as a modifiable upstream lever for SPM generation.

A. muciniphila colonises the mucosal layer and its extracellular vesicles reinforce tight junctions, increase mucus thickness, and improve barrier function. Pasteurised (non-live) preparations retain bioactivity and have an emerging human safety profile. The literature notes a nuanced mechanism: controlled mucin turnover by this species stimulates net mucosal regeneration.

Fecal microbiota transplantation has established efficacy for recurrent C. difficile and is under active investigation for IBD-associated chronic barrier dysfunction. For UC in remission with documented dysbiosis, the literature positions FMT as an emerging tool to restore the microbial substrate required for sustained mucosal integrity, particularly when SCFA-producing taxa are depleted.

GLP-2 directly enhances intestinal barrier integrity through cAMP and IGF-1 mediated pathways, driving mucosal epithelial proliferation, reducing permeability, and supporting villous/crypt architecture. The literature discusses GLP-2 analogues as a mechanistically compelling frontier for severe mucosal insufficiency beyond short bowel syndrome.

Regular moderate-intensity exercise is associated in the microbiome literature with increased abundance of SCFA-producing taxa including butyrate generators, and with reduced intestinal permeability markers. Exercise also supports vagal tone, further engaging the cholinergic anti-inflammatory pathway relevant to mucosal protection.

Approximately 20% of Europeans are non-secretors due to FUT2 loss-of-function variants, resulting in reduced fucosylation of MUC2 glycans and a structurally compromised mucus layer that predisposes to dysbiosis and barrier failure. The literature identifies FUT2 genotyping as a one-time testable genetic variable that stratifies patients for more intensive microbiome and glycosylation-targeted interventions.

Sustained mucosal remission in UC is inadequately captured by symptoms alone. The literature supports serial measurement of faecal calprotectin as a surrogate of mucosal inflammation, and urinary lactulose/mannitol ratio or serum zonulin as permeability indices to track barrier restoration over time.

Given the central role of Akkermansia muciniphila abundance, SCFA-producing taxa, and secondary bile acid-producing bacteria in mucosal barrier function, the literature supports stool microbiome sequencing to identify specific deficits guiding targeted probiotic and dietary interventions and to track restoration over time.

The pharmacomicrobiomics literature documents that numerous non-antibiotic drugs — including PPIs, NSAIDs, metformin, and antidepressants — significantly alter gut microbiota composition and barrier-relevant signalling pathways. In UC remission, clinicians should review the full medication list for agents with documented microbiome-disrupting profiles that may undermine mucosal repair efforts.

Butyrate's barrier-protective effects are well-documented in remission contexts; however, the literature notes that during active mucosal inflammation, high luminal butyrate concentrations may transiently exacerbate symptoms in some patients due to altered colonocyte metabolism. This protocol's supplementation steps are specifically framed for confirmed remission.

FMT carries risk of bacteraemia and systemic infection in immunocompromised individuals, including those on biologics or high-dose corticosteroids. The literature establishes FMT safety in immunocompetent hosts for CDI; for non-CDI indications including IBD, the safety profile in immunosuppressed patients requires specialist-level risk stratification.